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Abstract 
AIM: The purpose of this article was to systematically review the literature assessing the efficacy and safety of 
phase III clinical trials for each direct oral anticoagulant versus vitamin K antagonists and to design a ’’go-to’’ table 
for the prescriber. 
MATERIAL AND METHODS: A systematic review of specialist literature was conducted to identify RCTs which 
compared direct oral anticoagulants (DOACs) with standard warfarin treatment. Medline, Em-base, and the 
Cochrane databases were searched from January 2005- January 2019. The inclusion criteria were randomised 
controlled trials of oral anticoagulants in patients with non-valvular atrial fibrillation (NVAF). Four publications were 
phase III randomised control trials (RCTs) included in the final analysis. 
RESULTS: Regarding the primary outcome in RELY the results were 1.69% per 100-year patients (p/y) for 
Warfarin compared to 1.11% p/y dabigatran etexilate 150mg BD (twice daily). In ROCKET AF the rates of the 
primary outcome were 2.2% p/y for warfarin compared to 1.7% p/y for rivaroxaban 20 mg OD (once daily). In 
ARISTOTLE trial the rates of the primary outcome were 1.60% p/y for warfarin compared to 1.27% p/y for 
apixaban 5 mg BD. In ENGAGE AF TIMI, the rates of the primary outcome were 1.50% p/y for warfarin compared 
to 1.18% p/y for edoxaban 60mg BD. 
CONCLUSION: DOACs showed to be either noninferior or superior to warfarin with regards to the primary 
outcome with better safety patterns. Our ’’go-to’’ table provides a supportive tool for physicians in preventing 
medical errors when managing patients on oral anticoagulants. 
 
 
 
 
 
Introduction 
 
Atrial Fibrillation (AF) is one of the leading 
causes of cardiovascular morbidity and mortality 
worldwide [1]. The incidence and prevalence of AF 
have been increasing in recent years up to the point 
that one in four middle-aged adults in Europe and the 
US will develop this common cardiac arrhythmia [2], 
[3]. The above numbers reflect a growing number of 
patients requiring anticoagulants for stroke prevention. 
The clinical management of patients with non-
valvular AF (NVAF) has improved in recent years with 
the introduction of direct oral anticoagulant agents 
(DOACs) [4]. In the last decade, the four DOACs: 
dabigatran etexilate, rivaroxaban, apixaban and 
edoxaban have been used for the prevention of stroke 
and systemic embolism for people with NVAF with 
one or more risk factors: prior stroke or transient 
ischaemic attack; age 75 years or older; hypertension; 
diabetes mellitus; symptomatic heart failure [5]. 
Several characteristics distinguish DOACs 
from vitamin K antagonists (VKAs): rapid onset of 
action (1-3 h), do not require bridging with parenteral 
anticoagulants and there is no need for routine 
monitoring of anticoagulation. Additionally, DOACs 
have similar (7-15 h) half-lives and are partially 
eliminated by the kidney: 85% of dabigatran etexilate, 
50% of edoxaban, 33% of rivaroxaban, and 27% of 
apixaban [5]. Patients who are taking Warfarin should 
be aware of the potential risks and benefits of 
switching to DOACs and their level of international 
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normalised ratio (INR) control taken into consideration 
when switching between anticoagulants [5], [6]. 
The availability of several drugs with similar 
efficacy and safety for stroke prevention in NVAF 
patients offers a selection for prescribers and users. 
Consequently, prescribers should have a good 
knowledge of these agents’ characteristics and the 
trials in which their use was established to counsel 
and care for the growing number of patients on oral 
anticoagulants.  
The decision to take lifelong drugs such as 
oral anticoagulants should be made in collaboration 
between a patient and their doctor after an informed 
discussion about the risks and benefits of all the 
different drugs [7]. Medical professionals, particularly 
busy general practitioners/family doctors can find 
difficulties in keeping up to date with all the current 
guidelines and the new emerging drugs used in 
medical practice. If prescribers are better informed, 
then they can proficiently counsel their patients and 
collaborate with them when initiating an oral 
anticoagulant. 
The purpose of this article was to 
systematically review the literature assessing the 
efficacy and safety of phase III clinical trials for each 
DOAC versus VKAs used in stroke prevention in 
patients with NVAF. Also, it aimed to design a ‘’go-to’’ 
table for the prescriber to make an informed decision 
when comparing the oral anticoagulant drugs. 
 
 
Material and Methods 
 
A systematic review of specialist literature 
was conducted to identify phase III randomised 
control trials (RCTs) in patients receiving DOACs 
compared with standard warfarin treatment. Medline, 
Embase, and the Cochrane databases were searched 
from January 2005- January 2019 with no language 
restrictions using medical keywords to identify RCTs 
including ’’Dabigatran’’, ’’Rivaroxaban’', ’’Apixaban’’, 
’’Edoxaban’’, ’’Atrial Fibrillation’’, ’’Humans’’, 
’’Randomized Controlled Trial’’. After combining the 
results and removing duplicates, the titles and 
abstracts were screened in 50 studies (Figure 1).  
The full text of eight publications was 
retrieved and evaluated for eligibility, and four articles 
were phase III RCTs included in the final analysis. 
Studies had to meet the following inclusion criteria: 
randomised controlled trials of VKAs and DOACs in 
patients with NVAF. The research was excluded if 
patients were not followed up, if these were not 
randomised trials, and if papers were guidelines or 
any expert opinions.  
 
Figure 1: Prisma flow diagram illustrating the study selection 
process 
 
 
 
Results 
 
Four phases III clinical trials were evaluated, 
and in Table 1 and Table 2 we have compared the 
characteristics of phase III clinical trials for each 
DOAC that was on the market at the time of this 
study. Due to the heterogeneity of the key 
parameters, analysis of the statistical data was not 
attempted. 
Table 1: Phase III clinical trials NOACs purpose and specific 
data characteristics 
Study Name RELY 2009 ROCKET AF 
2011 
ARISTOTLE 
2012 
ENGAGE AF 
TIMI 48 2013 
Purpose Dabigatran 
etexilate 150 mg 
BD or 110 mg 
BD to open-label 
dose adjusted 
Warfarin 
Rivaroxaban 20 
mg OD to dose-
adjusted 
Warfarin  
Apixaban 5 mg 
BD to dose-
adjusted 
Warfarin  
Edoxaban 30 mg 
OD and 60 mg 
OD to dose-
adjusted 
Warfarin  
Method-all were 
Prospective 
randomised 
pivotal phase III  
clinical trial 
unblinded  double-blind, 
double-dummy 
double-blind, 
double-dummy 
double-blind, 
double-dummy  
Number of 
patients 
18113 14246 18201 21105 
Follow up 
(years) 
2 1.9 1.8 2.8 
CHADS2 2.1 3.5 2.1 2.8 
TTR (%) 64% 55% 62% 68% 
Females (%) 37% 39% 35% 37% 
Age mean 
(years) 
71 73 70 72 
Jadad score 3 5 5 5 
RE-LY (Randomised Evaluation of Long-Term Anticoagulation Therapy); ROCKET AF 
(Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K 
Antagonism for Prevention of Stroke and Embolism Trial in AF); ARISTOTLE (Apixaban 
for Reduction in Stroke and Other Thromboembolic Events in AF); ENGAGE AF-TIMI 48 
(The Effective Anticoagulation with Factor Xa Next Generation in AF- Thrombolysis in 
Myocardial Infarction 48). 
 
ROCKET-AF (rivaroxaban), ARISTOTLE 
(apixaban) and ENGAGE AF TIMI (edoxaban) were 
double-blind double-dummy trials. RELY (dabigatran 
etexilate) and ARISTOTLE trials had a similar number 
of patients of approximately 18100. The follow-up 
period in all trials ranged from 1.8-2.8 years. RELY 
and ARISTOTLE participants had an equal CHADS2 
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score of 2.1. ENGAGE AF TIMI and ROCKET AF 
participants had a CHADS2 score of 2.8 and 3.5, 
respectively. Time in the therapeutic range INR (TTR) 
varied from 64%, 55%, 62% and 68% respectively.  
Table 2: Phase III clinical trials DOACs efficacy and bleeding 
rates 
Study name and  
purpose 
Primary Outcome Bleeding/Mortality of 100 patients per year 
RE-LY  
 
2009 
Rates of the primary outcome 
(stroke or systemic embolism): 
1.69% p/y warfarin 
1.53% p/y dabigatran etexilate 
110 mg BD-noninferiority 
1.11% p/y dabigatran etexilate 
150 mg BD-superiority 
The rate of major bleeding: 
3.36% p/y warfarin 
2.71% p/y dabigatran etexilate 110 mg BD 
3.11% p/y dabigatran etexilate 150 mg BD 
 
The rate of hemorrhagic stroke: 
0.38% p/y warfarin 
0.12% p/y dabigatran etexilate 110 mg BD 
0.10% p/y dabigatran etexilate 150 mg BD 
 
The mortality rate: 
4.13%p/y warfarin 
3.75% p/y dabigatran etexilate 110 mg BD 
3.64% p/y dabigatran etexilate 150 mg BD 
ROCKET AF  
 
2011 
Rates of the primary outcome 
(stroke or systemic embolism): 
2.2 %p/y warfarin 
1.7% p/y rivaroxaban 20 mg OD 
noninferiority 
The rate of nonmajor bleeding: 
14.5% p/y warfarin 
14.9% p/y rivaroxaban 20 mg OD 
 
The rate of major bleeding: 
3.4% p/y warfarin 
3.6% p/y rivaroxaban 20 mg OD 
 
The rate of gastrointestinal bleeding: 
2.2% p/y warfarin 
3.2% p/y rivaroxaban 20 mg OD 
 
The rate of hemorrhagic stroke: 
0.7% p/y warfarin 
0.5% p/y rivaroxaban 20 mg OD 
 
The mortality rate: 
2.2% p/y warfarin 
1.9% p/y rivaroxaban 20 mg OD 
ARISTOTLE  
 
2012 
Rates of the primary outcome 
(stroke or systemic embolism): 
1.60% p/y Warfarin 
1.27% p/y Apixaban 5 mg BD 
superiority 
The rate of major bleeding: 
3.09% p/y warfarin 
2.13% p/y apixaban 5 mg BD 
 
The rate of hemorrhagic stroke: 
0.47% p/y warfarin 
0.24% p/y apixaban 5 mg BD 
 
The mortality rate: 
3.94% p/y warfarin 
3.52% p/y apixaban 5 mg BD 
ENGAGE AF TIMI 
48  
 
2013 
Rates of the primary outcome 
(stroke or systemic embolism): 
1.50% p/y Warfarin 
1.18% p/y Edoxaban 60 mg OD 
1.61% p/y Edoxaban 30 mg OD 
noninferiority 
The rate of major bleeding: 
3.43% p/y warfarin 
2.75% p/y edoxaban 60 mg OD 
1.61% p/y edoxaban 30 mg OD 
 
The rate of gastrointestinal bleeding: 
1.23% p/y warfarin 
1.51% p/y edoxaban 60 mg OD 
0.82% p/y edoxaban 30 mg OD 
 
The rate of hemorrhagic stroke: 
0.47% p/y warfarin 
0.26% p/y edoxaban 60 mg OD 
0.16% p/y edoxaban 30 mg OD 
 
The mortality rate: 
3.17% p/y warfarin 
2.74% p/y edoxaban 60 mg OD 
2.71% p/y edoxaban 30 mg OD 
 
Regarding the primary outcome in RELY the 
results were 1.69% per 100-year patients (p/y) for 
warfarin compared to 1.53% p/y dabigatran etexilate 
110 mg BD and 1.11% p/y dabigatran etexilate 150 
mg BD. In ROCKET AF the rates of the primary 
outcome were 2.2% p/y for warfarin compared to 
1.7% p/y for rivaroxaban 20 mg OD. In ARISTOTLE 
trial the rates of the primary outcome were 1.60% p/y 
for warfarin compared to 1.27% p/y for apixaban 5 mg 
BD. In ENGAGE AF TIMI the rates of the primary 
outcome were 1.50% p/y for warfarin compared to 
1.18% p/y for edoxaban 60 mg BD and 1.61% p/y for 
edoxaban 30 mg BD. Taking into consideration all the 
important literature in oral anticoagulation for NVAF 
we designed a comprehensive but simple to follow 
’’go-to’’ table (Table 3) [8], [9], [10], [11], [12], [13], 
[14], [15] to aid the prescribers worldwide. 
 
 
Table 3: Oral Anticoagulants Specific Information A Prescriber 
Support Tool 
 Warfarin Dabigatran 
etexilate 
Rivaroxaban Apixaban Edoxaban 
Dose/Frequency INR Dependent OD 150 mg BD 20 mg OD 5 mg BD 60 mg OD 
Peak/Half-life 3-5 days 
Half-life 40 hours 
2 days 
Half-life 12-14 
hours 
2-3 days 
Half-life 5-13 
hours 
1-2 days 
Half-life 8-15 
hours 
1-2 days 
Half-life 9-11 
hours 
Reduced dose  N/A 110 mg BD 15 mg OD 2.5 mg BD 30 mg OD 
Age  N/A Age > 80 years 
Also consider in > 
75years 
No dose 
adjustment 
Age > 80 years No dose 
adjustment 
Weight  Extreme weight > 
120 kg 
BMI > 40 kg/m2 
< 50 kg No dose 
adjustment 
< 60 kg < 60 kg 
Renal  Not affected CrCl < 5 0mL/min 
CI CrCl < 30 
mL/min 
 
85% 
CrCl < 15-49 
mL/min 
CI CrCl < 15 
mL/min 
 
33% 
Creatinine > 133 
micromoles/L or > 
1.5 mg/dl 
CI CrCl < 
15mL/min 
27% 
CrCl < 15-49 
mL/min 
CI CrCl < 15 
mL/min 
 
50% 
Interactions  
 
 
 
CAUTION IF 
Abciximab 
Alteplase 
Amiodarone 
Amoxicillin 
Aprepitant 
Antiplatelets 
Azathioprine 
Azoles (fluco,mico, 
itra,vori) 
Barbiturates 
Bosentan 
Carbamazepine 
Chloramphenicol 
Ciprofloxacin 
Clarithromycin 
Coamoxiclav 
Capecitabine 
Danazol 
Disulfiram 
Doxycycline 
Erythromycin 
Fibrinolytics 
Fibrates 
Flucloxacillin 
Fluorouracil 
Amiodarone 
Quinidine 
Clarithromycin 
Erythromycin 
 
 
Dose reduction: 
Verapamil 
(take at the same 
time) 
Clarithromycin 
Erythromycin 
Fluconazole 
Amiodarone 
Quinidine 
Diltiazem 
Naproxen 
 
Ciclosporin 
Tacrolimus 
Ketoconazole 
Itraconazole 
Voriconazole 
Posaconazole 
Amiodarone 
Quinidine 
 
Dose reduction: 
Clarithromycin 
Erythromycin 
Dronedarone 
Ciclosporin 
Tacrolimus 
Interactions  
 
 
 
AVOID IF 
Fluvastatin 
Fluvoxamine 
Fenofibrate 
Glucagon 
HIV protease 
inhibitors 
Ivermectin 
Levofloxacin 
Leflunomide 
Lymecycline 
Metronidazole 
Mercaptopurine 
Mesalamine 
NSAIDs 
Ofloxacin 
Quinidine 
Quinine 
Paclitaxel 
Prostacyclin 
Paracetamol 
Phenytoin 
Propofol 
Ketoconazole 
Itraconazole 
Voriconazole 
Posaconazole 
Dronedarone 
Rifampicin 
St John’s Wort 
Carbamazepine 
Phenytoin 
Phenobarbital 
Ritonavir 
Anticoagulants 
Tacrolimus 
Cyclosporin 
Ketoconazole 
Itraconazole 
Voriconazole 
Posaconazole 
Dronedarone 
Rifampicin 
St John’s Wort 
Carbamazepine 
Phenytoin 
Phenobarbital 
Ritonavir 
Anticoagulants 
Ketoconazole 
Itraconazole 
Voriconazole 
Posaconazole 
Dronedarone 
Rifampicin 
St John’s Wort 
Carbamazepine 
Phenytoin 
Phenobarbital 
Ritonavir 
Anticoagulants 
Ritonavir 
Rifampicin 
St John’s Wort 
Carbamazepine 
Phenytoin 
Phenobarbital 
Anticoagulants 
Dose reduction for 
DOACs if  
> 2 factors 
Rifampicin 
Ribavirin SSRI 
SNRI 
Steroids 
St John’s Wort 
Sulfasalazine 
Tamoxifen 
Terbinafine 
Vandetanib 
 Antiplatelets 
NSAIDs 
Systemic steroids 
Thrombocytopeni
a 
HASBLED > 3 
History of GI 
bleeding 
Recent surgery on 
critical organ 
(brain, eye) 
 
Liver  
  
AVOID IF 
Caution Elevated liver 
enzymes > 2 
upper limits of 
normal 
Hepatic 
impairment or liver 
disease expected 
to have any 
impact on survival 
Hepatic disease 
associated with 
coagulopathy 
Cirrhotic patients 
with Child-Pugh B 
and C 
Hepatic disease 
associated with 
coagulopathy 
Severe hepatic 
impairment 
Hepatic disease 
associated with 
coagulopathy 
Elevated liver 
enzymes > 2 
upper limits of 
normal 
total bilirubin ≥ 1.5 
x upper limit of 
normal 
Side effects Hair loss 
Rare vascular 
calcification and 
skin necrosis 
Oesophagitis 
Gastritis 
Duodenitis 
HASBLED > 3 
Anaemia 
Anaemia, 
Dizziness, 
Headache, 
Serious skin 
reactions (rare) 
Galactose 
intolerance 
Contains lactose 
Anaemia 
Anaemia, 
Dizziness, 
Headache 
High bilirubin 
High gamma 
glutamyltransferas
eskin rash 
Food interaction Brocolli/Green leafs 
vegetables, Garlic, 
Ginger, Grapefruit, 
Cranberry, Mango, 
Green tea, Alcohol 
X X 
must be taken 
with food 
X X 
Switching between 
anticoagulants 
Overlap until INR > 
2.0 
May take 5-10 days 
INR < 2.0 INR < 3.0 INR < 2.0 INR < 2.5 
Compliance aid Risk assessment No Yes Yes Yes 
Swallow whole Most brands of 
Warfarin tablets will 
disperse in water 
Yes (tartaric acid) No, can be 
crushed 
No, can be 
crushed 
Yes 
Missed Dose next dose as 
normal 
up to 6h before 
the next dose 
up to 12h before 
the next dose 
up to 6h before 
the next dose 
up to 12h before 
the next dose 
Bleeding All DOACs showed 
less Intracranial 
bleeding compared 
to 
Warfarin 
 
Antidote Vitamin K 
Prothrombin 
complex 
concentrate 
Major bleeding 
D150 mg BD = W 
D110 mg BD < W 
GI bleeding D150 
mg BD > W 
D110 mg BD = W 
Antidote 
Idarucizumab 
Haemodialysis 
Major bleeding 
R = W 
GI bleeding 
R > W 
No antidote 
Prothrombin 
complex 
concentrate 
Major bleeding 
A < W 
GI bleeding 
A = W 
No antidote 
Prothrombin 
complex 
concentrate 
Major bleeding 
E < W 
GI bleeding 
E60mg OD > W 
No antidote 
Prothrombin 
complex 
concentrate 
Specific 
Populations 
Obese >120kg 
Renal/Hepatic 
Impairment 
(caution) 
2nd-trimester 
pregnancy 
110mg BD if 
previous GI 
haemorrhage 
High bleeding risk 
HASBLED>3; 
150mg BD if 
recurrent stroke 
despite well 
managed VKA 
For Asian 
patients use 
another DOAC 
 
Preference for 
once daily 
preparations 
Previous GI 
haemorrhage 
High bleeding risk 
HASBLED>3 
Elderly patients 
Renal impairment 
Preference for 
once daily 
preparations 
 
High bleeding risk 
HASBLED>3 
Elderly patients 
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Discussion 
 
General characteristics of the four RCTs 
ROCKET AF, ARISTOTLE and ENGAGE AF 
TIMI were double-blind, double-dummy trials, whereas 
RELY was an open-label trial which suggested a 
possible bias for this trial. The RELY trial authors state 
the risk of bias was reduced by the implementation of 
several validated procedures, including blinded 
evaluation of outcome events [16]. RELY and 
ARISTOTLE trials had a similar number of patients of 
more than 18100, ROCKET AF had the smallest 
number of participants of 14246, whereas ENGAGE 
AF TIMI had the largest population of 21105 which 
showed that all trials were large trials of high 
importance. The follow-up period was similar in RELY, 
ROCKET AF and ARISTOTLE but considerably 
longer in ENGAGE AF TIMI at 2.8 years. RELY and 
ARISTOTLE participants had an equal CHADS2 score 
of 2.1. However, ENGAGE AF TIMI and ROCKET AF 
participants had a higher CHADS2 score of 2.8 and 
3.5, respectively. This was a significant finding and 
should be taken into account when choosing a 
particular DOAC for a patient. 
The mean percentage of TTR was lower in 
ROCKET-AF (55%) compared to TTR in ARISTOTLE 
(62%), RE-LY (64%) and ENGAGE AF TIMI (68%). 
This is also an important finding and should be taken 
into account particularly for patients who are switching 
from a VKA to a DOAC. In ROCKET AF the low TTR 
was interpreted as poor control of the patients 
anticoagulant status. Age and sex of the studied 
population were similar in all studies ranging from 70-
73 years and female percentage between 35-39%. 
These numbers show similarities with the general 
epidemiological data in AF (2). Finally, all the RCTs 
obtained a good Jadad score. 
 
RE-LY 
For the primary outcomes, dabigatran 
etexilate 150 mg twice daily was superior to warfarin, 
and dabigatran etexilate 110 mg twice daily was 
noninferior to warfarin. Major bleeding was 
significantly decreased with the 110 mg twice daily 
dose of dabigatran etexilate. However, the group on 
the 150 mg twice daily dose of dabigatran etexilate 
showed increased major bleeding events compared to 
warfarin. The risk of hemorrhagic stroke was also 
significantly lower with both the 110 mg and 150 mg 
doses [16]. These findings show that dabigatran 
etexilate was noninferior or superior (150 mg BD) 
when compared to warfarin, but the bleeding risk 
should be considered in both anticoagulants.  
Interestingly, the rate of myocardial infarction 
was higher with both doses of dabigatran etexilate 
compared with warfarin but not statistically significant. 
A reason for this was explained by Connolly et al., 
(RELY) that warfarin provides better protection 
against coronary ischaemic events compared to 
dabigatran [16] (Table 2). 
Dabigatran etexilate capsules contain coating 
with tartaric acid to enhance the gastric absorption 
which requires a more acidic environment. This acidity 
may explain the increased incidence of dyspeptic 
symptoms with both dabigatran etexilate doses [16]. 
This should be taken into consideration when 
prescribing dabigatran etexilate in patients with known 
gastro-oesophagal pathology. 
 
ROCKET AF 
For the primary outcomes, the trial 
demonstrated noninferiority for rivaroxaban compared 
with warfarin in patients with NVAF who were at 
moderate to high risk for stroke. Major bleeding was 
similarly reported for rivaroxaban and warfarin groups. 
However, less fatal bleeding and less intracranial 
haemorrhage were found in the rivaroxaban group. In 
contrast, gastrointestinal (GI) bleeding was more 
frequently reported in the rivaroxaban group [17]. 
Consequently, extra caution should be taken when 
prescribing rivaroxaban in patients with previous GI 
bleeding (Table 2). 
At the end of the trial, patients transitioning to 
open-label therapy had more strokes with rivaroxaban 
compared with warfarin [18]. Patel et al. explained that 
the difficulty in transitioning from blinded trial therapy 
to the open-label use of a VKA could have been the 
cause for this [17]. Presumably many patients who 
had previously been assigned to the warfarin group 
would have already had a therapeutic INR compared 
to the patients in the rivaroxaban group [17]. This 
should be taken into account when switching between 
anticoagulants. 
 
ARISTOTLE 
Granger at al described it was the only study 
of a DOAC that showed significantly lower rates of all-
cause mortality reported at 3.52% in the apixaban 
group compared to 3.94% in the warfarin group [19]. 
Apixaban has shown to be significantly more effective 
than warfarin, with fewer overall strokes and systemic 
emboli by 21%, major bleeding events by 31% and 
decreased mortality by 11% [19]. Consequently, 
further studies showed positive findings for apixaban 
in comparing DOACs indirectly. A meta-analysis of the 
above trials indicated that there were no statistically 
significant differences between dabigatran etexilate, 
rivaroxaban or apixaban in the incidence of stroke, 
systemic embolism and all-cause mortality [6], [18]. 
Additionally, apixaban was associated with a 
significantly lower incidence of all bleeding outcomes 
compared with rivaroxaban and a lower incidence with 
clinically relevant non-major bleeding compared to 
dabigatran etexilate 150 mg twice daily [18]. 
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ENGAGE AF TIMI 
This was the largest DOAC trial, and it 
showed that both once-daily regimens of edoxaban 
were noninferior when compared with warfarin 
regarding the primary outcome. Of note, the follow-up 
period in this trial was long, and the TTR was higher 
compared to the previous three DOAC trials. This 
illustrated good management of patients on oral 
anticoagulants within the trial. Edoxaban regimens 
were associated with significantly lower rates of 
bleeding and mortality from cardiovascular causes 
compared to warfarin [18]. The rates of life-
threatening bleeding, intracranial bleeding, and major 
bleeding plus clinically relevant non-major bleeding 
were significantly lower in the edoxaban group. 
However, the annualised rate of major gastrointestinal 
bleeding was higher with high dose edoxaban than 
with warfarin (1.51% vs 1.23%), but the 
gastrointestinal bleeding rate was lowest with low 
dose edoxaban (0.82%). Giugliano et al. stated that 
the rate of myocardial infarction was not altered with 
edoxaban, and there was no increase in the risk of 
stroke or bleeding when patients in the edoxaban 
groups made the transition to open-label 
anticoagulant therapy at the end of the study [20]. 
 
DOACs and specific patient characteristics 
DOACs appeared to be equally or more 
effective and safer than Warfarin in preventing 
systemic embolism irrespective of the patients’ 
comorbidities [6], [16], [17], [18], [20]. Subsequently, 
’’real world’’ studies showed that the risks of mortality, 
any bleeding, or major bleeding were significantly 
lower for apixaban and dabigatran etexilate compared 
with warfarin [18], [21]. We are in agreement with 
Shields et al. that direct comparison of the results 
from large, international, multicenter randomized 
control trials of DOACs versus warfarin for NVAF 
should be interpreted with caution due to differences 
in the mean CHADS2 score, TTR and rates of stroke 
and systemic embolism and hemorrhage in the 
warfarin group of the trials [15], [22]. 
In patients with NVAF with a significant risk of 
stroke, DOACs were reported as highly effective at 
preventing strokes compared to VKAs, and these 
provide a major improvement in the management of 
NVAF patients [23]. DOACs showed to have a more 
favourable safety profile and side effects, particularly 
for intracranial bleeding. Since the introduction of 
DOACs, there has been reported an increase in newly 
diagnosed patients with NVAF at risk of stroke who 
are receiving guideline-recommended therapy [4], 
[21]. 
Furthermore, due to the relatively recent 
introduction of these drugs, prescribers need to be 
aware of their characteristics, cautions and 
contraindications. Audits on prescribing oral 
anticoagulants reported frequent medical errors [23]. 
We agree with Heidbuchel et al., that the choice of the 
most appropriate DOAC for a patient should be based 
on the pharmacokinetics, pharmacodynamics and the 
integration of the clinical data concerning the patient’s 
characteristics [14]. Recommendations from EHRA 
(European Heart Rhythm Association) suggested that 
patients with a history or high risk of gastrointestinal 
bleeding may have a lower risk of bleeding 
complications with apixaban and low dose edoxaban 
compared with dabigatran etexilate, rivaroxaban or 
high dose edoxaban [14]. Moreover, there was 
reported some evidence that patients with a high risk 
for ischemic stroke may benefit from dabigatran 
etexilate 150 mg twice daily [24]. 
Regarding patient-centeredness, evidence 
was reported that patients adhere better to once daily 
medications compared with those medications taken 
twice daily. [25] Patient’s compliance was an 
important factor in the management of NVAF and data 
suggested in GARFIELD AF that patient refusal 
(11.2% for high-risk patients) has been the main 
patient factor affecting the rates of anticoagulation [4]. 
In patients without a contraindication to DOAC 
therapy, the selection among the agents was left 
primarily to physician and patient decision. 
Wilke et al. reviewed the preferences of AF 
patients towards anticoagulation and showed that 
stroke risk reduction and limited bleeding risk were the 
most important attributes for an NVAF patient when 
deciding about oral anticoagulation [26]. NVAF 
patients were willing to accept higher bleeding risks if 
a certain threshold in reduced stroke risk could be 
reached [7], [26]. Steinberg et al. considered that 
involving the patient in the decision making when 
selecting a DOAC was vital for optimal management 
in NVAF [27]. Therefore this article encourages 
physicians to counsel patients about the risks and 
benefits of treatment and work out which is the best 
oral anticoagulant agent based on their characteristics 
(Table 3). 
 
 
Conclusion 
 
Based on the results in phase III randomised 
control trials discussed in this article, DOACs have 
shown similar efficacy but better safety patterns when 
compared with warfarin for NVAF management. To 
safely use anticoagulants, physicians should take into 
account patient-specific factors and shared decision 
making when prescribing an oral anticoagulant. 
Our ‘’go-to’’ table provides a supportive tool 
for physicians in preventing medical errors when 
managing patients on oral anticoagulants. Finally, 
research should be continued in clinical trials 
particularly for the specific populations. 
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Implications for Research 
 
In this systematic review was summarised the 
important facts from the RCTs on oral anticoagulants. 
Also, a prescription tool was designed to aid family 
doctors/ prescribers in choosing the right agent for the 
right patient. 
 
 
Limitations 
 
Although we comprehensively reviewed and 
summarised the literature, our search was not 
exhaustive, and new data are emerging rapidly.  
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